
**NEOPROBE TO PRESENT AT RODMAN & RENSHAW CONFERENCE
CEO To Provide Business Update**

DUBLIN, OHIO – September 3, 2009 -- Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that its President and Chief Executive Officer, David Bupp, will present on Thursday, September 10, 2009 at 4:55PM ET, in the Fahnestock Salon, during the Rodman & Renshaw Annual Global Investment Conference to be held at the New York Palace Hotel in New York, New York. Mr. Bupp's presentation will provide an overview of the Company's technology and business strategy.

Interested parties can access a live, or an archived internet broadcast of the presentation at:

<http://www.wsw.com/webcast/rrshq15/neop.ob>

The presentation will be archived for 30 days.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan® CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com